Merus NV
NASDAQ:MRUS
Relative Value
The Relative Value of one MRUS stock under the Base Case scenario is 36.16 USD. Compared to the current market price of 47.02 USD, Merus NV is Overvalued by 23%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
MRUS Competitors Multiples
Merus NV Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
NL |
Merus NV
NASDAQ:MRUS
|
2.7B USD | 61.9 | -17.5 | -15.4 | -15.1 | ||
US |
Abbvie Inc
NYSE:ABBV
|
285.6B USD | 5.3 | 59.3 | 12.9 | 19.6 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
148.5B USD | 5.3 | 22.1 | 16.4 | 24.6 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.6B USD | 10.5 | 28.6 | 22.9 | 24 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.8B USD | 7.5 | 25 | 16.6 | 18.2 | ||
AU |
CSL Ltd
ASX:CSL
|
133B AUD | 6.1 | 35.1 | 21.3 | 26.4 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 168.6 | 6.8 | 8.9 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
42.6B USD | 6.2 | -9 | -9.5 | -8.2 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.5B USD | 3.3 | 27 | 13.8 | 17.3 | ||
KR |
Celltrion Inc
KRX:068270
|
39.3T KRW | 18.1 | 73.4 | 44.9 | 61.8 |